{"title":"Contributing Reviewers in 2022","authors":"","doi":"10.1055/s-0043-1768142","DOIUrl":"https://doi.org/10.1055/s-0043-1768142","url":null,"abstract":"","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"55 11","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120983580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Objective New-onset diabetes mellitus after transplantation (NODAT), also known as posttransplant diabetes mellitus, is a common complication after kidney transplantation. It is associated with an increased risk of graft failure and death. Therefore, minimizing the risk of NODAT is a priority after kidney transplantation. This study aimed to determine the incidence of NODAT, the risk factors for its development, and the therapeutic drugs used for its management. Patients and Methods This is an observational, retrospective study on kidney recipients who were followed up in our center in 2021. After excluding known diabetic patients, second transplant patients, and those with follow-up periods less than 6 months, 308 recipients were included in the study. Demographic, clinical, and laboratory data were collected from the patient records. The patients were categorized as diabetic or nondiabetic. Results All patients' mean age was 35.9±11.6 years (standard deviation). The male-to-female ratio was 2.13:1. The overall incidence of NODAT was 38.3%. The median time to NODAT diagnosis was 6 months. Patients older than 40 were more likely to develop NODAT (61.1%; p = 0.000). The prevalence of pretransplant body mass index (BMI) more than 25 was significantly higher (67.6%) in diabetic than among nondiabetic patients ( p = 0.000). NODAT patients were more likely to have had a rejection episode (65 vs. 35% in nondiabetic patients; p = 0.011). A high trough level of calcineurin inhibitors carried a significant risk of NODAT development. Tacrolimus trough level more than or equal to 10 ng/mL had an odds ratio of 57.9 (95% confidence interval [CI] 7.689–1262.2; p = 0.0007) for the development of NODAT. Likewise, a cyclosporine-A trough level more than or equal to 150 ng/mL had an odds ratio of 100.7 (95% CI: 7.31–4293.5; p = 0.0028). Conclusion NODAT incidence was high in this study. Older age, high BMI, prior rejection episode, steroid dose, and high calcineurin inhibitors trough levels were significant risk factors for developing NODAT.
{"title":"Incidence and Risk Factors for the Development of New-Onset Diabetes after Kidney Transplantation","authors":"Jamila S. Elamouri","doi":"10.1055/s-0043-1763275","DOIUrl":"https://doi.org/10.1055/s-0043-1763275","url":null,"abstract":"Abstract Objective New-onset diabetes mellitus after transplantation (NODAT), also known as posttransplant diabetes mellitus, is a common complication after kidney transplantation. It is associated with an increased risk of graft failure and death. Therefore, minimizing the risk of NODAT is a priority after kidney transplantation. This study aimed to determine the incidence of NODAT, the risk factors for its development, and the therapeutic drugs used for its management. Patients and Methods This is an observational, retrospective study on kidney recipients who were followed up in our center in 2021. After excluding known diabetic patients, second transplant patients, and those with follow-up periods less than 6 months, 308 recipients were included in the study. Demographic, clinical, and laboratory data were collected from the patient records. The patients were categorized as diabetic or nondiabetic. Results All patients' mean age was 35.9±11.6 years (standard deviation). The male-to-female ratio was 2.13:1. The overall incidence of NODAT was 38.3%. The median time to NODAT diagnosis was 6 months. Patients older than 40 were more likely to develop NODAT (61.1%; p = 0.000). The prevalence of pretransplant body mass index (BMI) more than 25 was significantly higher (67.6%) in diabetic than among nondiabetic patients ( p = 0.000). NODAT patients were more likely to have had a rejection episode (65 vs. 35% in nondiabetic patients; p = 0.011). A high trough level of calcineurin inhibitors carried a significant risk of NODAT development. Tacrolimus trough level more than or equal to 10 ng/mL had an odds ratio of 57.9 (95% confidence interval [CI] 7.689–1262.2; p = 0.0007) for the development of NODAT. Likewise, a cyclosporine-A trough level more than or equal to 150 ng/mL had an odds ratio of 100.7 (95% CI: 7.31–4293.5; p = 0.0028). Conclusion NODAT incidence was high in this study. Older age, high BMI, prior rejection episode, steroid dose, and high calcineurin inhibitors trough levels were significant risk factors for developing NODAT.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116947664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Beshyah, Aly B Khalil, A. Beshyah, M. Benbarka, I. Sherif
Abstract Objective Thyroxine (T4) therapy is taken on an empty stomach and no food is taken for a short period. During Ramadan fasting (RF), Muslim patients may face difficulties taking levothyroxine as recommended. Materials and Methods We performed a mixed methods study of an online survey of 218 physicians to explore their perceptions and practices. Also, we interviewed a sample of 172 hypothyroid patients to establish their practices and source of information. Their median age was 46 (17–90) years; they had hypothyroidism for a median of 5 years and took a median thyroxine dose of 100 µg daily. Furthermore, we attempted to explore the effects of RF on available thyroid function tests. Results Consultants were 58.4%, and the most represented specialty was endocrinology, 46.1%. Regarding the impact of RF on T4 therapy, 52.3% thought the RF was not clinically relevant in most patients on T4 replacement. However, 27.5% thought RF affects T4 replacement therapy in a clinically relevant manner. About 77.1% of respondents reported giving advice routinely to all patients on T4 replacement during RF. One hundred sixty-four respondents were split between recommending taking the medications with Iftar , Suhour , or other times. Most respondents (73.9%) do not repeat measurements of thyroid hormone levels after Ramadan unless needed during their scheduled clinic visit. On the other hand, 50.3% of the patients confirmed that their physician advised them to take their thyroxine during Ramadan, whereas 40.4% could not recall receiving any advice. About 59.9% of the patients took thyroxine with Iftar , 23.8% with Suhour , and 16.3% at different times. In those patients where thyroid function tests were available before and after RF, serum thyroid-stimulating hormone and serum-free T4 did not show a specific pattern in the group as a whole and with subgroups. Conclusion There is variation in the advice that hypothyroid patients receive on taking thyroxine during Ramadan and in their practices. Further studies are needed to determine the best timing for thyroxine replacement.
{"title":"Thyroxine Replacement Therapy during Ramadan Fasting: Physicians' and Patients' Perceptions and Practices","authors":"S. Beshyah, Aly B Khalil, A. Beshyah, M. Benbarka, I. Sherif","doi":"10.1055/s-0043-176327","DOIUrl":"https://doi.org/10.1055/s-0043-176327","url":null,"abstract":"Abstract Objective Thyroxine (T4) therapy is taken on an empty stomach and no food is taken for a short period. During Ramadan fasting (RF), Muslim patients may face difficulties taking levothyroxine as recommended. Materials and Methods We performed a mixed methods study of an online survey of 218 physicians to explore their perceptions and practices. Also, we interviewed a sample of 172 hypothyroid patients to establish their practices and source of information. Their median age was 46 (17–90) years; they had hypothyroidism for a median of 5 years and took a median thyroxine dose of 100 µg daily. Furthermore, we attempted to explore the effects of RF on available thyroid function tests. Results Consultants were 58.4%, and the most represented specialty was endocrinology, 46.1%. Regarding the impact of RF on T4 therapy, 52.3% thought the RF was not clinically relevant in most patients on T4 replacement. However, 27.5% thought RF affects T4 replacement therapy in a clinically relevant manner. About 77.1% of respondents reported giving advice routinely to all patients on T4 replacement during RF. One hundred sixty-four respondents were split between recommending taking the medications with Iftar , Suhour , or other times. Most respondents (73.9%) do not repeat measurements of thyroid hormone levels after Ramadan unless needed during their scheduled clinic visit. On the other hand, 50.3% of the patients confirmed that their physician advised them to take their thyroxine during Ramadan, whereas 40.4% could not recall receiving any advice. About 59.9% of the patients took thyroxine with Iftar , 23.8% with Suhour , and 16.3% at different times. In those patients where thyroid function tests were available before and after RF, serum thyroid-stimulating hormone and serum-free T4 did not show a specific pattern in the group as a whole and with subgroups. Conclusion There is variation in the advice that hypothyroid patients receive on taking thyroxine during Ramadan and in their practices. Further studies are needed to determine the best timing for thyroxine replacement.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"96 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128645500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Management of diabetes lends itself very well to several classical rules of good clinical practice, an elaborationofwhich is out of the scope of this short story. However, a couple of these are noteworthy. “Diagnosis should precede treatment as much as possible except formeasures of resuscitation” applies to diabetes as to all other conditions. In diabetes, diagnosis and classification are the same. Hence, a serious attempt to classify diabetes at the time of diagnosis or as soon as possible after that ismandatory.1 Inparticular,when thepatient’s characteristics are atypical, or events do not follow the expected course, making assumptions under these circumstances can be very dangerous.2 In this vignette, an unusual case of diabetes in a young woman is presented and discussed with an analysis of lessons to be learned. The present case report exemplifies several themes of “not expecting the expected,” “not making unfounded assumptions,” and “ignoring several alert signals.” In theMerriam-Webster dictionary, the idiom “in the nick of time”means just before the last moment when something can be changed or something terrible will happen.3 Many examples are medical, for instance, “The ambulance arrived in the nick of time” or “The doctor arrived in the nick of time. The patient’s life was saved”. Hence, the choice of the title is not for fun, but it is perhaps thebest description of the case as the story unfolds.
糖尿病的管理很好地适用于临床实践的几个经典规则，对这些规则的详细阐述超出了这篇短篇小说的范围。然而，其中有几个值得注意。“除采取复苏措施外，诊断应尽可能先于治疗”适用于糖尿病和所有其他疾病。糖尿病的诊断和分类是一样的。因此，在诊断时或诊断后尽快对糖尿病进行分类是必须的特别是，当患者的特征是非典型的，或者事件没有按照预期的过程进行时，在这种情况下做出假设可能是非常危险的在这个小插图中，一个不寻常的年轻女性糖尿病病例被提出并讨论与教训的分析。本案例报告举例说明了“不期望预期”、“不做毫无根据的假设”和“忽略几个警报信号”的几个主题。在韦氏词典中，习语“In the nick of time”指的是在事情可以改变或可怕的事情将要发生的最后一刻之前许多例子都是医疗方面的，例如，“救护车及时赶到了”或“医生及时赶到了”。病人的生命得救了。”因此，书名的选择并不是为了好玩，但随着故事的展开，它可能是对案件的最好描述。
{"title":"Lesson of the Week: In the Nick of Time!","authors":"S. Beshyah","doi":"10.1055/s-0043-1761195","DOIUrl":"https://doi.org/10.1055/s-0043-1761195","url":null,"abstract":"Management of diabetes lends itself very well to several classical rules of good clinical practice, an elaborationofwhich is out of the scope of this short story. However, a couple of these are noteworthy. “Diagnosis should precede treatment as much as possible except formeasures of resuscitation” applies to diabetes as to all other conditions. In diabetes, diagnosis and classification are the same. Hence, a serious attempt to classify diabetes at the time of diagnosis or as soon as possible after that ismandatory.1 Inparticular,when thepatient’s characteristics are atypical, or events do not follow the expected course, making assumptions under these circumstances can be very dangerous.2 In this vignette, an unusual case of diabetes in a young woman is presented and discussed with an analysis of lessons to be learned. The present case report exemplifies several themes of “not expecting the expected,” “not making unfounded assumptions,” and “ignoring several alert signals.” In theMerriam-Webster dictionary, the idiom “in the nick of time”means just before the last moment when something can be changed or something terrible will happen.3 Many examples are medical, for instance, “The ambulance arrived in the nick of time” or “The doctor arrived in the nick of time. The patient’s life was saved”. Hence, the choice of the title is not for fun, but it is perhaps thebest description of the case as the story unfolds.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":" 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120834275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Gulf Association for Endocrinology and Diabetes 11 Years on","authors":"W. Hussein, N. Aljuhani","doi":"10.1055/s-0043-1761197","DOIUrl":"https://doi.org/10.1055/s-0043-1761197","url":null,"abstract":"","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125417395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Journal of Diabetes and Endocrine Practice—Five Years On!","authors":"S. Beshyah","doi":"10.1055/s-0043-1761196","DOIUrl":"https://doi.org/10.1055/s-0043-1761196","url":null,"abstract":"","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"67 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114190449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Objectives: This concise article aims to (a) review the role of vitamin D in bone health, (b) discuss the consequences of vitamin D deficiency, (c) analyze the use of vitamin D to prevent and treat osteoporosis and (d) explore if the evidence pendulum is switching back on the beneficial effects of vitamin D. Materials and Methods: A narrative nonsystematic review of the literature was done thematically to answer the questions stated in the objectives above. Results: A literature review suggests that vitamin D deficiency can be a real clinical condition that warrants recognition and management, particularly in high-risk groups. The optimal vitamin D level is likely more than or equal to 50 nmol/L (20 ng/mL). The established consequences of vitamin D deficiency in adults include osteomalacia and osteoporosis. Moreover, whether vitamin D supplementation reduces falls and fractures in subjects with baseline vitamin D more than 50 nmol/L (20 ng/mL) is not confirmed. However, vitamin D supplementation is still needed for patients with osteoporosis and those at increased risk of vitamin D deficiency. Finally, there is no justification for measuring 25-hydroxyvitamin D in the general population. Conclusions: For patients at increased risk for osteoporosis, those with vitamin D deficiency, or both, it remains reasonable to consider vitamin D supplementation (800–1,000 IU/d or more), consistent with recommendations of multiple societies.
{"title":"Vitamin D and Bone Health 2022: Is the Evidence Pendulum Switching Backward on Its Benefits?","authors":"H. Saadi","doi":"10.1055/s-0043-1763273","DOIUrl":"https://doi.org/10.1055/s-0043-1763273","url":null,"abstract":"Abstract Objectives: This concise article aims to (a) review the role of vitamin D in bone health, (b) discuss the consequences of vitamin D deficiency, (c) analyze the use of vitamin D to prevent and treat osteoporosis and (d) explore if the evidence pendulum is switching back on the beneficial effects of vitamin D. Materials and Methods: A narrative nonsystematic review of the literature was done thematically to answer the questions stated in the objectives above. Results: A literature review suggests that vitamin D deficiency can be a real clinical condition that warrants recognition and management, particularly in high-risk groups. The optimal vitamin D level is likely more than or equal to 50 nmol/L (20 ng/mL). The established consequences of vitamin D deficiency in adults include osteomalacia and osteoporosis. Moreover, whether vitamin D supplementation reduces falls and fractures in subjects with baseline vitamin D more than 50 nmol/L (20 ng/mL) is not confirmed. However, vitamin D supplementation is still needed for patients with osteoporosis and those at increased risk of vitamin D deficiency. Finally, there is no justification for measuring 25-hydroxyvitamin D in the general population. Conclusions: For patients at increased risk for osteoporosis, those with vitamin D deficiency, or both, it remains reasonable to consider vitamin D supplementation (800–1,000 IU/d or more), consistent with recommendations of multiple societies.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131764479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Khaled Al Dahmani, B. Afandi, T. Elhadd, W. Hussein
,
，
{"title":"Free Communications of the Tenth Gulf Association of Endocrinology and Diabetes Annual Congress, Riyadh, Saudi Arabia, November 3–5, 2022","authors":"Khaled Al Dahmani, B. Afandi, T. Elhadd, W. Hussein","doi":"10.1055/s-0043-1763279","DOIUrl":"https://doi.org/10.1055/s-0043-1763279","url":null,"abstract":",","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123368597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Beshyah, A. E. Bashier, B. Afandi, Mohammed Naman Mohammed, E. Abdelgadir, A. Beshyah
Abstract Objectives We aimed to ascertain physicians' attitudes and practices and evaluate patients' knowledge of antithyroid drugs (ATDs). Also, we would like to review the quality of patients' information on the Internet (in Arabic) concerning ATDs' including agranulocytosis. Methods A mixed methods study design was employed, including an online physician questionnaire, structured interviews of patients on ATDs, and evaluation on web sites containing patients' information in Arabic. Results Most physicians (82.6%) thought the frequency of agranulocytosis in patients receiving antithyroid medications is 1 to 5 per 1,000 per annum. Nearly 72% of the participants reported educating their patients about the risk of agranulocytosis when they receive ATDs regularly verbally only. Most physicians thought patients should be warned about sore throat and fever. More participants would measure a white blood cell (WBC) count only if a patient developed suggestive symptoms (57.0%) than those who do it routinely (43.0%). If a patient receiving ATDs develops suspicious symptoms, participants thought that the most efficient way to deal with this is to attend the nearest hospital emergency department (37.2%). Less thought they can go to any facility with a laboratory that can do WBC count (29.8%) or contact their usual endocrine clinic (24.4%). Nearly half of the patients (49%) were aware of the side effects of ATDs, but only 17 respondents (17.3%) identified one or both of the two most typical symptoms of agranulocytosis. The quality of the information received was evaluated as “not good at all” or “poor” by 19.2%. Over two-thirds (69.7%) of participants thought the amount of information was about right. Most participants (72.5%) preferred receiving information on side effects during consultations with their physicians. Since starting ATDs, 37.0% of patients have experienced different symptoms suggestive of agranulocytosis in various combinations. However, only one-third (12/37) had an urgent blood count. A review of 190 selected Arabic patient information Internet sites revealed a significant variation in patient advice. Six percent 11/190 (5.8%) of the sites can be considered good. Conclusions The findings of suboptimal and inconsistent perceptions and practices of physicians and patients put patients with ATD in the Middle East at increased risk and call for more action from professional and patient advocacy groups.
{"title":"Physicians' and Patients' Perceptions and Practices Concerning Antithyroid Drug-Induced Agranulocytosis","authors":"S. Beshyah, A. E. Bashier, B. Afandi, Mohammed Naman Mohammed, E. Abdelgadir, A. Beshyah","doi":"10.1055/s-0043-1761438","DOIUrl":"https://doi.org/10.1055/s-0043-1761438","url":null,"abstract":"Abstract Objectives We aimed to ascertain physicians' attitudes and practices and evaluate patients' knowledge of antithyroid drugs (ATDs). Also, we would like to review the quality of patients' information on the Internet (in Arabic) concerning ATDs' including agranulocytosis. Methods A mixed methods study design was employed, including an online physician questionnaire, structured interviews of patients on ATDs, and evaluation on web sites containing patients' information in Arabic. Results Most physicians (82.6%) thought the frequency of agranulocytosis in patients receiving antithyroid medications is 1 to 5 per 1,000 per annum. Nearly 72% of the participants reported educating their patients about the risk of agranulocytosis when they receive ATDs regularly verbally only. Most physicians thought patients should be warned about sore throat and fever. More participants would measure a white blood cell (WBC) count only if a patient developed suggestive symptoms (57.0%) than those who do it routinely (43.0%). If a patient receiving ATDs develops suspicious symptoms, participants thought that the most efficient way to deal with this is to attend the nearest hospital emergency department (37.2%). Less thought they can go to any facility with a laboratory that can do WBC count (29.8%) or contact their usual endocrine clinic (24.4%). Nearly half of the patients (49%) were aware of the side effects of ATDs, but only 17 respondents (17.3%) identified one or both of the two most typical symptoms of agranulocytosis. The quality of the information received was evaluated as “not good at all” or “poor” by 19.2%. Over two-thirds (69.7%) of participants thought the amount of information was about right. Most participants (72.5%) preferred receiving information on side effects during consultations with their physicians. Since starting ATDs, 37.0% of patients have experienced different symptoms suggestive of agranulocytosis in various combinations. However, only one-third (12/37) had an urgent blood count. A review of 190 selected Arabic patient information Internet sites revealed a significant variation in patient advice. Six percent 11/190 (5.8%) of the sites can be considered good. Conclusions The findings of suboptimal and inconsistent perceptions and practices of physicians and patients put patients with ATD in the Middle East at increased risk and call for more action from professional and patient advocacy groups.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129916918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The Emirates Diabetes Society (EDS) consensus guidelines for the management of type 2 diabetes were published in 2020.1 To produce the consensus guideline, the EDS convened a panel of experts who were tasked with adapting key research findings and international guidelines for local use. The final publication was reviewed by the panel and represented its collective analysis and recommendations. It was particularly based on the 2019 guideline on diabetes, prediabetes, and cardiovascular disease produced by the European Association for the Study of Cardiology (ESC) in collaboration with the European Association for the Study of Diabetes (EASD),2 and on the 2020 Standards of Care from the American Diabetes Association (ADA).3 The process was facilitated by an unrestricted grant from Novo Nordisk who did not participate in any of the meetings or the drafting of the manuscript. Key recommendations were made on screening, interventions for prediabetes, structured education, physical activity, nutrition therapy, and pharmacotherapy. The recommendations on pharmacotherapy took account of the person’s risk of cardiovascular disease. How do the EDS consensus guidelines compare with other guidelines and consensus statements on the management of type 2 diabetes, and what approaches could be taken when the EDS consensus guidelines are reviewed? What Are Guidelines and Consensus Statements?
{"title":"Guidelines on the Management of Type 2 Diabetes","authors":"M. Fisher","doi":"10.1055/s-0043-1761205","DOIUrl":"https://doi.org/10.1055/s-0043-1761205","url":null,"abstract":"The Emirates Diabetes Society (EDS) consensus guidelines for the management of type 2 diabetes were published in 2020.1 To produce the consensus guideline, the EDS convened a panel of experts who were tasked with adapting key research findings and international guidelines for local use. The final publication was reviewed by the panel and represented its collective analysis and recommendations. It was particularly based on the 2019 guideline on diabetes, prediabetes, and cardiovascular disease produced by the European Association for the Study of Cardiology (ESC) in collaboration with the European Association for the Study of Diabetes (EASD),2 and on the 2020 Standards of Care from the American Diabetes Association (ADA).3 The process was facilitated by an unrestricted grant from Novo Nordisk who did not participate in any of the meetings or the drafting of the manuscript. Key recommendations were made on screening, interventions for prediabetes, structured education, physical activity, nutrition therapy, and pharmacotherapy. The recommendations on pharmacotherapy took account of the person’s risk of cardiovascular disease. How do the EDS consensus guidelines compare with other guidelines and consensus statements on the management of type 2 diabetes, and what approaches could be taken when the EDS consensus guidelines are reviewed? What Are Guidelines and Consensus Statements?","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131515289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：